Carrier Global Corporation (“Carrier”) is a leading global provider of heating, ventilating and air conditioning (HVAC), refrigeration, fire, security and building automation technologies, and is listed on the New York Stock Exchange. Beijer Ref AB (publ) (“Beijer Ref”) provides commercial and industrial refrigeration as well as heating and air conditioning products and is listed on Nasdaq Stockholm.
Vinge has advised VEF Ltd, an investment company whose Swedish Depositary Receipts (“SDR”) are listed on Nasdaq First North, in connection with a directed share issue whereby VEF receives approximately SEK 522 million in issue proceeds.
Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue in the pharmaceutical company Xbrane Bipharma, whereby Xbrane Biopharma receives gross proceeds of approximately SEK 200 million.
Vinge assisted the STRAX group in refinancing and the entering into a facilities agreement with Proventus Capital Partners IV (“Proventus”) as lender in the total amount of EUR 30 million.
Vinge has advised Offentliga Hus i Norden AB (publ) (“Offentliga Hus”) in connection with its listing on Nasdaq First North Premier Growth Market (“Nasdaq First North Premier”). The prospectus was published on 13 October 2020 and the first day of trading on Nasdaq First North Premier was 23 October 2020.
Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives gross proceeds of approximately SEK 265 million.
Vinge advises the Swedish state in connection with the recapitalization of SAS. The recapitalization plan, which includes State aid that has been approved by the EU Commission, restores SAS’ equity by SEK 14.25 billion and secures approximately SEK 12 billion of new funding.
Vinge has advised Nordic Paper Holding AB (publ) (“Nordic Paper” or the “Company”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on 12 October 2020 and the first day of trading on Nasdaq Stockholm was 22 October 2020.
The loan agreement with the EIB grants Oncopeptides access to an unsecured loan facility of up to EUR 40 million. The loan may be used to further support the clinical development of melflufen and the company’s transition from a R&D company into a fully integrated global biopharmaceutical company. In connection with the loan agreement, Oncopeptides has entered into a warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.
